Talaris
Latest round
- Series B
Last raised
- Sep 2020
Total raised
- $215M
Investors
- 12
About Talaris
, formerly known as Regenerex, operates as a biotechnology company that develops cellular therapies. The company was founded by Chief Scientific Officer Suzanne Ildstad. In 2008, Regenerex initiated Phase 2 clinical trial of allogeneic cell therapy (FCR001) in living donor kidney transplant (LDKT) patients. In 2010, the first FCR001-dosed LDKT patient was successfully weaned off all immunosuppression. He remained immunosuppression-free. In 2013, Regenerex partnered with Novartis to advance trials of FCR001.03 million in an IPO conducted on Nasdaq and listing the company under ticker TALS. Talaris is a late-clinical stage, cell therapy company developing methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that aims to transform solid organ transplantation, certain autoimmune diseases, and certain non-malignant blood, immune, and metabolic disorders. Its product candidate, FCR001, is a one-time, investigational cell therapy that contains three distinct cell types: hematopoietic stem cells, facilitating cells, and aßTCR+ T-cells, that rebuild the hematopoietic and immune system of the recipient. The company is advancing three clinical programs of Facilitated Allo-HSCT Therapy: FREEDOM-1, a randomized, controlled, open-label Phase 3 registration trial in the US of FCR001 in 120 adult living donor kidney transplants (LDKT) recipients; FREEDOM-2, a Phase 2 trial that evaluates the potential for FCR001 to induce durable immune tolerance in patients who have previously received a kidney from a living donor, a process called delayed tolerance; and FREEDOM-3, a Phase 2 trial exploring the clinical activity of FCR001 in patients with a severe form called scleroderma, a complex and heterogeneous systemic autoimmune disease affecting multiple tissues and organs. Talaris, Inc.
Who invested in Talaris
12 investors across 2 rounds
See all investors in Talaris
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Talaris
Who invested in Talaris?
Talaris has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Talaris raised?
Talaris has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Talaris last raise money?
Talaris's most recent round on record is a Series B, in Sep 2020.
What does Talaris do?
, formerly known as Regenerex, operates as a biotechnology company that develops cellular therapies.
Where is Talaris headquartered?
Talaris is headquartered in Louisville, US.
Which VCs invest in companies like Talaris?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Talaris's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Talaris? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.